Serum 14-3-3; matrix metalloproteinases and their inhibitors' levels before and after cardiovascular surgery in diabetic and non-diabetic patients

Diabetes Research and Clinical Practice

Volumn 90, Issue 3, 2010, Pages 305-311

  Mohajerani, Alireza ^a   Ghahary, Aziz ^b   Khuramizadeh, Mohammadreza ^c   Larijani, Bagher ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute wound; Diabetes mellitus; Matrix metalloproteinase; Serum

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; CAPTOPRIL; DILTIAZEM; ENALAPRIL; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; INTERSTITIAL COLLAGENASE; LOSARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PROPRANOLOL; PROTEIN 14 3 3; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIAMTERENE; VALSARTAN; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; EXTRACELLULAR MATRIX; HUMAN; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; SURGICAL WOUND; TREATMENT RESPONSE; WOUND HEALING;

14-3-3 PROTEINS; ADULT; CORONARY ARTERY BYPASS; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; WOUND HEALING;

EID: 78649462933     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.09.006     Document Type: Article

References (30)

1. Ghahary A., Karimi-Busheri F., Marcoux Y., Li Y., Tredget E.E., Taghi Kilani R., et al. Keratinocyte-releasable stratifin functions as a potent collagenase-stimulating factor in fibroblasts. J Invest Dermatol 2004, 122:1188-1197.
2. Medina A., Scott P.G., Ghahary A., Tredget E.E. Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil 2005, 26:306-319.
3. Boston P.F., Jackson P., Thompson R.J. Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J Neurochem 1982, 38:1475-1482.
4. Takeoka T. Cerebrospinal fluid examination in the infectious j meningitis and encephalitis. Nippon Rinsho 1997, 55:809-814.
5. Katz A.B., Taichman L.B. A partial catalog of proteins secreted by epidermal keratinocytes in culture. J Invest Dermatol 1999, 112:818-821.
6. Ramm G., Larance M., Guilhaus M., James D.E. A role for 14-3-3 in insulin-stimulated GLUT4 translocation through its interaction with the RabGAP AS160. J Biol Chem 2006, 81:29174-29180.
7. Merla G., Howald C., Antonarakis S.E., Reymond A. The subcellular localization of the ChoRE-binding protein, encoded by the Williams-Beuren syndrome critical region gene 14, is regulated by 14-3-3. Hum Mol Genet 2004, 13:1505-1514.
8. Tengrup I., Hallmans G., Agren M.S. Granulation tissue formation and metabolism of zinc and copper in alloxan-diabetic rats. Scand J Plast Reconstr Surg Hand Surg 1988, 22:41-45.
9. Rahimi R., Nikfar S., Larijani B., Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 2005, 59:365-373.
10. Bitar M.S., Farook T., Wahid S., Francis I.M. Glucocorticoid-dependent impairment of wound healing in experimental diabetes: amelioration by adrenalectomy and RU 486. J Surg Res 1999, 82:234-243.
11. Chung A.W., Hsiang Y.N., Matzke L.A., McManus B.M., van Breemen C., Okon E.B. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 2006, 99:140-148.
12. Kilani R.T., Maksymowych W.P., Aitken A., Boire G., St-Pierre Y., Li Y., et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 2007, 34:1650-1657.
13. Xu L., McLennan S.V., Lo L., Natfaji A., Bolton T., Liu Y., et al. Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. Diabetes Care 2007, 30:378-380.
14. Ashcroft G.S., Mills S.J. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest 2002, 10:615-624.
15. Pitteloud N., Mootha V.K., Dwyer A.A., Hardin M., Lee H., Eriksson K.F., et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28(July (7)):1636-1642.
16. Black E., Vibe-Petersen J., Jorgensen L.N., Madsen S.M., Agren M.S., Holstein P.E., et al. Decrease of collagen deposition in wound repair in type 1 diabetes independent of glycemic control. Arch Surg 2003, 138:34-40.
17. Spravchikov N., Sizyakov G., Gartsbein M., Accili D., Tennenbaum T., Wertheimer E. Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 2001, 50:1627-1635.
18. Hehenberger K., Hansson A. High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors. Cell Biochem Funct 1997, 15:197-201.
19. Lam E., Tredget E.E., Marcoux Y., Li Y., Ghahary A. Insulin suppresses collagenase stimulatory effect of stratifin in dermal fibroblasts. Mol Cell Biochem 2004, 266:167-174.
20. Ghahary A., Marcoux Y., Karimi-Busheri F., Li Y., Tredget E.E., Kilani R.T., et al. Differentiated keratinocyte-releasable stratifin (14-3-3 Sigma) stimulates MMP-1 expression in dermal fibroblasts. J Invest Dermatol 2005, 124:170-177.
21. Brandner J.M., Zacheja S., Houdek P., Moll I., Lobmann R. Expression of matrix metalloproteinases, cytokines, and connexins in diabetic and nondiabetic human keratinocytes before and after transplantation into an ex vivo wound-healing model. Diabetes Care 2008, 3:114-120.
22. Saarialho-Kee U.K. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998, 290:47-54.
23. Soo C., Shaw W.W., Zhang X., Longaker M.T., Howard E.W., Ting K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 2000, 105:638-647.
24. Lobmann R., Schultz G., Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care 2005, 28:461-471.
25. Muller M., Trocme C., Lardy B., Morel F., Halimi S., Benhamou P.Y. Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. Diabet Med 2008, 25:419-426.
26. Lobmann R., Ambrosch A., Schultz G., Waldmann K., Schiweck S., Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002, 45:1011-1016.
27. Gharagozlian S., Svennevig K., Bangstad H.J., Winberg J.O., Kolset S.O. Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin Pathol 2009, 9:7.
28. Derosa G., D'Angelo A., Scalise F., Avanzini M.A., Tinelli C., Peros E., et al. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007, 22:361-370.
29. Derosa G., D'Angelo A., Tinelli C., Devangelio E., Consoli A., Miccoli R., et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007, 33:129-134.
30. Liu Y., Min D., Bolton T., Nubé V., Twigg S.M., Yue D.K., et al. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care 2009, 32:117-119.